Xenon (XENE) has released an update.
Xenon Pharmaceuticals is set to participate in the BofA Securities 2024 CNS Therapeutics Virtual Conference on October 7, 2024, to discuss its progress in neuroscience-focused therapeutics. The company, known for its advanced clinical developments, including its lead product Azetukalner for neurological and psychiatric disorders, will be presenting via a live webcast available on the Xenon website.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.
